Saturday, January 09, 2010
Optimal management of recurrent ovarian cancer. [Int J Gynecol Cancer. 2009] - PubMed result
Note: several years ago Cary Vera Garcia (deceased) published an article about ovarian cancer as a chronic disease. It was an excellent article and she felt using the term chronic as it may apply to ovarian cancer 'Devalued a Survivor's Challenge'. Dr Markman wrote a response concerning the clinical use of the word 'chronic' as it may apply to ovarian cancer. So, 'very serious chronic' is a new term which is interesting.
Sandi
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Int J Gynecol Cancer. 2009 Dec;19 Suppl 2:S40-3.
Optimal management of recurrent ovarian cancer.
Markman M.
Department of Gynecologic Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. mmarkman@mdanderson.org
The development of an optimal management approach in recurrent ovarian cancer requires careful consideration of a number of important factors including (a) response to and severity/persistence of toxicity associated with prior therapy, (b) existence of relevant trial data (particularly phase 3 studies), (c) patient interest in participating in clinical trials, (d) cost of (and ability to pay for) particular anti-neoplastic drug regimens, and (e) patient choice. It is likely that the increasing availability of biologically active novel agents (and combination programs) in this clinical setting will add to the difficulty of defining optimal therapy in recurrent/resistant ovarian cancer, which, in many individuals, can be reasonably considered a very serious chronic disease process.
abstract: Symptom control pts with recurrent OC: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistan
Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer.
Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antia
Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.
Friday, January 08, 2010
Biological Mechanisms Linking Obesity and Cancer Risk: New Perspectives - Annual Review of Medicine, 61(1):301 - Abstract
"While public health policies aimed at curbing the underlying causes of the obesity epidemic are being implemented, there is a parallel need to better understand the biological processes linking obesity and cancer as a prerequisite to the development of new approaches to prevention and treatment."
Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies* - Annual Review of Medicine, 61(1):35 - Abstract
Laboratory of Molecular Medicine and Neuroscience, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892; email: majorg@ninds.nih.gov
"Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the white matter of the human brain caused by lytic infection of oligodendrocytes with the human polyomavirus JCV. Although the majority of PML cases occur in severely immune-suppressed individuals, with HIV-1 infection as the predominant factor, PML has been increasingly diagnosed in patients treated with biological therapies such as monoclonal antibodies that modulate immune system functions...."
Patient-Centered Medical Homes in Ontario | Health Care Reform
Some interesting observations in this article including:
"Per capita, Canada has one third fewer active physicians than the United States, 15% more primary care physicians, and half as many specialists. Consequently, the heavy responsibilities of Canadian specialists promote shared care with family physicians, and specialists rarely see patients without referral. In the United States, only 30% of visits to specialists occur through referrals,5 and patients are likely to see multiple specialists."
April 17-21, 2010 in Washington, DC. - AACR 101st Annual Meeting 2010
New Concepts in Organ Site Research:
Recent Advances in Ovarian Cancer Research
Co-Chairpersons: Christopher P. Crum, Brigham and Women's Hospital, Boston, MA, and Shelley S. Tworoger, Brigham and Women's Hospital, Boston, MA
* David D. Bowtell, Peter MacCallum Cancer Center, Melbourne, Australia
* Elise C. Kohn, National Cancer Institute, Bethesda, MD
* Martin Widschwendter, Institute for Women's Health, University College London, London, United Kingdom
* Alicja Wolk, National Institute of Environmental Medicine, Stockholm, Sweden
Dear Advocates: (sponsorship) 2010 ACMG Annual Clinical Genetics Meeting
January 8th, 2009:
Dear advocates,
We are now accepting applications for the Advocates Partnership Program at the American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting, March 24-28 in Albuquerque, New Mexico.
The Advocates Partnership Program aims to foster new connections among members of the genetics community. Highlights for participants include engaging in thought-provoking discussions about clinical genetics and informatics, and attending exclusive daily briefings with ACMG staff and professionals working in your area of interest. The ACMG preliminary meeting schedule is available at http://www.acmgmeeting.net/schedule.php
Acceptance into the Advocates Partnership Program includes waived full registration to the ACMG Annual Clinical Genetics Meeting. Furthermore, participants will be reimbursed for up to $250 for transportation, hotel accommodations, or airfare.
We welcome applications from individuals interested in the field of clinical genetics. Individuals who hold ACMG membership or those who could be a potential candidate for membership are not eligible to apply for the Advocates Partnership Program.
To apply, please download the application form from http://www.geneticalliance.org/advocates.opportunities.
Please return it to tmurza@geneticalliance.org no later than Friday, February 5, 2010.
Priority will be given to individuals who previously have not participated in the Advocates Partnership Program.
Please forward this message to your friends and colleagues.
If you have any questions, please contact Tetyana Murza at tmurza@geneticalliance.org or (202) 966-5557 ext. 205. We look forward to hearing from you.
Best,
Genetic Alliance
Thursday, January 07, 2010
press release: Theralase Technologies Research Successfully Destroys Breast Cancer cells
preclinical studies to come in 2010
full free access-focus on Lynch Syndrome Ultradeep Sequencing of a Human Ultraconserved Region Reveals Somatic and Constitutional Genomic Instability
"Genomic instability is a common trait of cancer cells and plays a pivotal role in promoting carcinogenesis in several hereditary tumours. One of the best-known examples is the Lynch syndrome, an autosomal dominant condition associated with heterozygous mutations in mismatch repair (MMR) genes. During their lifespan, individuals affected by the Lynch syndrome...... The tumourigenic process starts when mutations hit oncogenes and/or tumour suppressors, often in actively renovating tissues such as endometrium, ovary, and colon. In the latter case, the genetic condition is known as hereditary non-polyposis colorectal cancer (HNPCC), which represents the most common form of inherited colorectal cancer.... Since more than 90% of HNPCC show MSI this has become a common diagnostic marker..."
JCO Editorial: Generalizing the Results of Cancer Clinical Trials
See also Table 1:Occult Influences of the Clinical Trial Setting on the Generalizability of Results - Differences in the Patient Population
"As clinical trials increasingly become a global enterprise, issues of generalizability will increase in importance. It will be essential to ensure that the conduct of a trial and its subsequent reporting include attention to aspects that influence generalizability, so that determinations of whether observations and conclusions reached in one geographic setting, or within one type of health care system, are applicable to the policy makers and practitioners from other settings."
JCO Editorial: Biomarkers of Antiangiogenic Therapy: How Do We Move From Candidate Biomarkers to Valid Biomarkers?
"Thus, these candidate biomarkers should continue to be actively explored in trials of antiangiogenic agents in patients, to get closer to the goal of improving and individualizing cancer therapy."
Journal of Oncology — An Open Access Journal Role of lymphadenectomy in early and advanced ovarian cancer
click on 'pdf' top right hand corner
full free access: Journal of Oncology —Role of lymphadenectomy in early and advanced ovarian cancer
full free access - click on the 'pdf' box - top right corner
There Is a New Pre-Symptomatic Screening Test for Ovarian Cancer Coming From Arrayit Corporation, and It Will Be Available Soon - OvaDx(TM)
Note: The test will soon be submitted to the FDA for approval
BJC - Abstract: Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity
Note: ovarian cancer patients were included in this phase 1 study but abstract gives limited information
DNAPrint Genomics - Ovanome
Note: As far as I can tell this test still needs approvals
OVANOME:
Ovanome is a genetic test for predicting an ovarian cancer patient’s response to first-regimen Taxol¹ and carboplatin (TC) chemotherapy. 30% of chemo-naive women do not respond to TC treatment and DNAPrint™ research shows that this problem is largely a function of genetic polymorphism.
Biotech News & Online Store - Belinostat phase II trial initiated in platinum-resistant ovarian cancer by the Gynecologic Oncology Group (GOG) supported by
The study:
A Phase II evaluation of Belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.
UK: i LEARN u LEARN events
Our ‘i LEARN – u LEARN’ events are taking place in March 2010.
These are six interactive meetings that will be held in
* London (1 & 17 March 2010)
* Belfast (4 March 2010)
* Cardiff (9 March 2010)
* Liverpool (12 March 2010)
* Edinburgh (15 March 2010)
At these meetings, you can find out more about regulation in the health sector and take part in various activities where you can lend your voice to some ongoing debates. We will be supported at all meetings by representatives from the health professional regulatory bodies. Places at these meetings are limited, so we encourage you to register early to attend these events. You can register by emailing us at reception@chre.org.uk or by calling us on 020 7389 8030.
Pallimed: A Hospice & Palliative Medicine Blog
This most recent update has some good information and includes some Twitter comments regarding Palliative/Hospice care comments.
Wednesday, January 06, 2010
HealthNewsReview.org: Study: Ginkgo biloba has no effect on Alzheimer's, dementia
Study: Ginkgo biloba has no effect on Alzheimer's, dementia
free full access: Current status of maintenance therapy for advanced ovarian cancer
Note: below the abstract click on 'pdf download article' (full free access)
"This article reviews the current status of maintenance therapy for advanced ovarian cancer, including phase III evidence and new and upcoming trials."
full free access (2008) Prevention of Venous Thromboembolism* — CHEST gynecologic cancers are included
This is a very long article, includes gynecologic cancer surgery as well as other topics regarding blood clots including for at-risk travellers:
"Cancer patients undergoing surgery have at least twice the risk of postoperative DVT and more than three times the risk of fatal PE encountered by noncancer patients who are undergoing similar procedures."
press release: Vermillion Unsecured Creditors Approve Proposed Plan of Reorganization -- FREMONT, Calif., Jan. 6 /PRNewswire-FirstCall/ --
About the OVA1 Test
The OVA1 Test is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers --- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta2-Microglobulin (Beta2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) --- and a proprietary algorithm to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned.
OVA1(TM) Test is a trademark of Vermillion Inc.
OncoGenex - OGX-427
"We are also considering a randomized Phase 2 clinical trial investigating OGX-427 in ovarian cancer," said Scott Cormack, President and Chief Executive Officer of OncoGenex."
full free access: TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use — Cold Spring Harbor Perspectives in Biology
Somatic TP53 mutations occur in almost every type of cancer at rates from 38%–50% in ovarian and..........TP53 mutations, but not p53 positive immunohistochemistry (IHC), have been consistently associated with poor prognosis in cancers such as breast, colorectal, head and neck, and leukemia.....In terms of clinical applications, TP53 mutations have proven to be extremely complex biomarkers. Despite impressive progress in mechanistic understanding of p53 structure and function, p53 research has not yet generated applications of wide impact on cancer management and therapy."
Tuesday, January 05, 2010
abstract/full text: Gene silencing of glypican-3 in clear cell carcinoma of the ovary renders it more sensitive to the apoptotic agent paclitaxel
"Clear cell carcinoma has been classified as a subgroup of EOC and reported to be an interesting histologic type with unique clinical features. CCC showed a poorer prognosis compared to serous adenocarcinoma because it tended to be resistant to antineoplastic agents, including paclitaxel.
CCC comprises more than 15% of EOC cases in Japan, although it represents 8–10% of all EOC cases in the USA. Therefore, it is important to establish new treatment strategies to improve the prognosis of CCC patients.
GPC3 regulates cell growth either positively or negatively depending on the cell type. Genetic and functional studies showed that glypicans regulate the signaling activity of various morphogens, including Wnts, Hedgehogs, bone morphogenic proteins, and fibroblast growth factors. Previous studies showed that GPC3 was overexpressed in Wilms' tumor, hepatocellular carcinoma, and hepatoblastoma. In ovarian carcinoma, GPC3 was overexpressed in yolk sac tumor and CCC.(15–17) However, GPC3 function in CCC was unclear. Furthermore, we investigated the role of this molecule in the sensitivity of CCC to paclitaxel, which is a key drug for ovarian cancer, using shRNA targeting GPC3.
Taken together, our data could support the use of GPC3-targeted therapies for CCC patients. We suggest that therapy targeting to GPC3 may be a novel treatment strategy that could potentially help to prevent the appearance, progression, and/or recurrence of CCC."
full free access:
http://www3.interscience.wiley.com/cgi-bin/fulltext/122614981/HTMLSTART
Longwoods Publishing - TOP TEN BEST READ DOCUMENTS/ARTICLES FOR DECEMBER 2009
Monday, January 04, 2010
Risk Factors for Pancreatic Cancer « Rush InPerson
Certain hereditary conditions, including:
- Hereditary pancreatitis
- multiple endocrine neoplasia type I syndrome (MEN)
- hereditary nonpolyposis colon cancer (HNPCC or Lynch Syndrome)
- von Hippel-Lindau syndrome, ataxia-telangiectasia
- familial atypical multiple mole melanoma syndrome (FAMMM)
- BRCA2
- Peutz-Jeghers syndrome
- cystic fibrosis
New platinum compound shows promise in tumor cells-in research Milaplatin combination
New platinum compound shows promise in tumor cells
"The new compound, mitaplatin, combines cisplatin with another compound, dichloroacetate (DCA), which can alter the properties of mitochondria selectively in cancer cells. Cancer cells switch their mitochondrial properties to change the way they metabolize glucose compared to normal cells, and DCA specifically targets the altered mitochondria, leaving normal cells intact."
Long-term decline in cervical cancer inciden...
In perspective??
2006 Canadian deaths=380..........need for a population based vaccine is ????
2006 Canadian deaths=380..........need for a population based vaccine is ????
Sunday, January 03, 2010
Saturday, January 02, 2010
"Dear Cancer" - Varian RapidArc's Letter Writing Campaign "Dear Cancer"
Note: at this moment the website shows that 1,770+ letters have been written, only 14 ovarian cancer contributions
(to check out the website click on the logo for further information)
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer: A Panacea or Just an Obstacle Course for the Patient?
comment: although this discussion is related to colorectal cancer, awareness of these concerns is relevant to our community, I believe
Journal of Pediatric Surgery : Can we preoperatively risk stratify ovarian masses for malignancy?
"1- to 8-year age group had the highest percentage of malignancies"
Friday, January 01, 2010
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG ph 111
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial
"For currently unknown reasons, administering PLD with carboplatin appears to substantially reduce the incidence of platinum-associated hypersensitivity reactions."
Comparison of extended colectomy and limited resection in patients with Lynch syndrome
includes prophylactic (preventative) surgery
Guidelines for the management of ovarian cancer during pregnancy.
"If chemotherapy is indicated, we recommend delaying administration, if possible, until after the delivery or at least after 20 weeks in order to minimize the potential fetal toxicity".
Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer?
Note: It's unfortunate that early stages of ovarian cancers were not included in this study.
Thursday, December 31, 2009
Ovarian metastases from breast cancer
"Ovarian disease (cancer) was diagnosed at a median of 5 years after breast cancer. Seventy-five percent of patients were asymptomatic, and advanced-stage pelvic extent or extra-abdominal metastases were observed in 41.5% of patients. The median survival was 3 years..."
Safety Considerations and Potential Interactions of Vitamins: Should Vitamins Be Considered Drugs?
"...A, E, D can cause serious adverse events."
Identifying novel autoantibody signatures in ovarian cancer
CONCLUSIONS: Protein microarrays are suitable for autoantibody discovery in ovarian cancer but the signatures are of low frequency.
full free access EDITORIAL: Designing Early Detection Programs for Ovarian Cancer -- JNCI
free full access: Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case-Control Study -- JNCI
Note: small study, did not include family history of colorectal cancer (Lynch Syndrome); clear cell ovarian subtype
THE RESEARCH ARTICLE:
Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case-Control Study -- Anderson et al., 10.1093/jnci/djp438 -- JNCI Journal of the National Cancer Institute
Wednesday, December 30, 2009
Assessing lead time of selected ovarian cancer biomarkers | Science Codex
Assessing lead time of selected ovarian cancer biomarkers
"Concentrations of the biomarkers CA125, human epididymis protein 4 (HE4), and mesothelin began to rise 3 years before clinical diagnosis of ovarian cancer, according to a new study published online December 30 in the Journal of the National Cancer Institute. However, the biomarkers became substantially elevated only in the last year prior to diagnosis. The stage of the cancer at the time of marker elevation is not known.
CA125, HE4, mesothelin, B7-H4, decoy receptor 3, and spondin-2 have been identified as potential ovarian cancer biomarkers, but their behavior in the pre-diagnostic period, with the exception of CA125, has not been evaluated previously."
Tuesday, December 29, 2009
I don't need a 'war' to fight my cancer. I need empowering as a patient
O bituaries routinely inform us that so-and-so has died "after a brave battle against cancer".
Of course, we will never read that so-and-so has died "after a pathetically feeble battle against cancer".
Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With Maintenance Bevacizumab As First-Line Chemotherapy for Advanced Mullerian Tumors
Forty-five women (73%) had ovarian cancer, 10 (16%) had peritoneal cancer, four (6%) had fallopian tube cancers, and three (5%) had uterine papillary serous tumors.
Monday, December 28, 2009
Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening
"Our findings reinforce the recommendation that women diagnosed with endometrial cancer before the age of 45 years and women with synchronous endometrial and ovarian cancer be screened for LS, irrespective of family history."
Anthropometric Measures and Risk of Epithelial Ovarian Cancer: Results From the Nurses' Health Study
Anthropometric: understanding human physical variation
Ohio Hospital Program Increases Interaction Between Nurses, Patients
"In October 2008, staff members at Riverside Methodist Hospital (RMH) in Columbus, OH, approached Sheryl Tripp, MSN, RN-BC, nurse manager for the gynecology/gynecology-oncology (gyn/gyn-onc) surgical unit, in hopes of changing the way nurses were issuing patient reports."
Longwoods Healthcare Blog: “What Do Patients Want? A Critical Look at Healthcare Delivery in Canada”
"But the debate, like the health system itself, has been dominated largely by vested interests. I’m watching it, just like you do, from afar. People like the insurance industry and dogmatists from all across the political spectrum – right and left. Rarely in that debate do we hear from patients, or more specifically, from patients without a political agenda or not hired by a group with a message to sell. Rarer still is to hear patients articulate what they want or expect from a health system. And that’s not unique to the US discussion; we have the same problem in Canada...."
Sunday, December 27, 2009
blog: The New Mammogram Guidelines - What You Need to Know (U.S.)
The New Mammogram Guidelines - What You Need to Know
Saturday, December 26, 2009
Friday, December 25, 2009
Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites?
"THE NECESSITY FOR CLINICAL TRIALS EVALUATING BEVACIZUMAB TREATMENT IN PATIENTS WITH MALIGNANT ASCITES
Based on the preclinical and clinical data outlined above, we strongly suggest that the efficacy and safety of the i.p. application of bevacizumab for the treatment of malignant ascites be assessed in stringently designed clinical studies. Bevacizumab is generally well tolerated and has an acceptable toxicity profile consisting primarily of hypertension and proteinuria. Other rare but important adverse effects, however, include delayed wound healing, arterial thrombosis, and bleeding [118]. Finally, a potentially serious adverse effect of bevacizumab is gastrointestinal perforation and, although comparably infrequent, this potentially life-threatening complication has generated significant clinical interest. Overall, gastrointestinal perforation was found to be an uncommon but well-documented side effect of treatment in the phase III trials of bevacizumab, as well as in subsequent surveillance trials, with a reported incidence of 1%–2% [106, 107, 109, 119]. Though strong evidence identifying specific risk factors is lacking, investigators have urged caution when treating patients with known bowel implants or a large tumor burden, prior radiation, and recent surgery or bowel obstruction [106, 119, 120]."
Chicago Cancer Genome Project studies genetics of 1,000 tumors
The project also will gather genetic data on how the genes expressed by tumors evolve over time. Whenever possible, the researchers will compare tumor samples taken from a patient before and after treatments, to learn how cancers accumulate additional genetic changes that enable them to resist radiation or chemotherapy or to spread to distant sites.
Thursday, December 24, 2009
open access: Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management
Subjects carrying a mutation in one of the MMR genes have a higher risk for developing colorectal cancer, but also for endometrial carcinoma and malignancies of the stomach, small bowel, ovaries, upper uroepithelial tract, biliary tract, skin and brain.(pancreas)
Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008
More importantly, tumour type and stage of disease are essential for drawing conclusions from such findings.
Carey et al.
2008 244 advanced ovarian cancer EORTC QLQ-C30 Performance status and global QOL scores at baseline were prognostic factors for both progression-free survival and overall survival.
Gupta et al.
2008 90 ovarian cancer Ferrans and Powers QLI No statistically significant prognostic
association of patient satisfaction with QOL was observed with survival.
Wednesday, December 23, 2009
The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper ab
The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum.
Tuesday, December 22, 2009
Radiation recall dermatitis -- Guarneri and Guarneri, 10.1503/cmaj.090320 -- Canadian Medical Association Journal
Includes potential for radiation recall and specific treatment therapies such as: 5-fluorouracil, hydroxyurea, vinblastine,
methotrexate, adriamycin, etoposide, tamoxifen, bleomycin, melphalan, paclitaxel, docetaxel, gemcitabine, pegylated liposomal
doxorubicin, interferon α-2b, antituberculous drugs and simvastatin.
Medical News: Abdominal Surgery Risky for Older Patients
These associations held for patients with cancer and other diagnoses, and for both elective and nonelective procedures (P<0.001).
Prevalence, Demographics, and Psychological Associations of Sleep Disruption in Patients With Cancer: University of Rochester Cancer Center-Community Clinical Oncology Program
Insomnia is prevalent, underrecognized, undermanaged, and understudied among patients with cancer receiving chemotherapy.
Monday, December 21, 2009
Sunday, December 20, 2009
Doctor and Patient - Holding Doctors Accountable for Medical Errors - NYTimes.com
Editorial Comment: The emphasis of this article seems to place a rather large burden on physicians which is not totally warranted.
Doctor and Patient - Holding Doctors Accountable for Medical Errors - NYTimes.com
Q. What is a major patient safety area that still needs to be addressed?
A. Ten years ago, we approached patient safety as a series of system flaws; we believed that most errors were committed by good competent people doing something no more complicated than forgetting a cellphone. But in the last few years some of us in the patient safety field have begun to feel uneasy about that approach. When there are reasonably safe standards available, what do you do when people simply don’t adhere to them? At some point, it’s no longer a “systems problem.”
Saturday, December 19, 2009
Friday, December 18, 2009
Effects of antioxidant supplements on cancer prevention: meta-analysis of randomized controlled trials -- Myung et al. 21 (1): 166 -- Annals of Oncology
Cancer diagnostic assessment programs: standards for the organization of care in Ontario
related to:
Cancer diagnostic assessment programs: standards for the organization of care in Ontario
Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma pts
full free access: Journal of Ovarian Research:
Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients
Thursday, December 17, 2009
Urgent notice: Ovarian Cancer woman needs help - pls respond Vancouver, BC
An ovarian cancer woman is being discharged to home hospice care, however, her wishes are to die within an institutional complex hospice care facility. Physician hospice support would be required. Apparently these services are not available for patients/people with complex care. IF you can assist with these system issues please respond in an urgent manner.
Annexin IV is differentially expressed in clear cell carcinoma of the ovary
clear cell vs serous - potential biomarker
definition: Slacktivism - Wikipedia, the free encyclopedia
Note: this is a 'new' term maybe and was found through a non-profit organizations's poll - rather disparaging term considering volunteerism is a large focus of NP's wouldn't you think? Comments?
Slacktivism - Wikipedia, the free encyclopedia
Wednesday, December 16, 2009
1988 - CA 125 in the Follow–Up of Patients with Ovarian Cancer; Acta Obstetricia et Gynecologica Scandinavica - 67(1):Pages 53-58 - Informa Healthcare
Ca 125 in the Follow–Up of Patients with Ovarian Cancer; Acta Obstetricia et Gynecologica Scandinavica - 67(1):Pages 53-58 - Informa Healthcare: "It is useful for monitoring the course of chemotherapy, but normal levels do not rule out the possibility of persistent or recurrent disease."
NIH Consumer Health Request for Information
NIH Consumer Health Request for Information: "We would like to hear from you!
The NIH Office of Communication and Public Liaison (OCPL) and the NIH Director's Council of Public Representatives (COPR) have partnered to develop a Consumer Health Information RFI in response to a Directive by President Barack Obama to all Federal agencies calling for greater transparency, public participation, and collaboration.
In conjunction with the NIH goals for public input and effective dissemination of science-based health resources and information to the public, the RFI will provide insight and better understanding of the health information needs and information-seeking behaviors of NIH health consumer audiences. Information gathered will assist the agency in developing and disseminating health, medical, and scientific information to a broader variety of audiences."
How Do I Apply? - Application Process, Congressionally Directed Medical Research Programs
How Do I Apply? - Application Process, Congressionally Directed Medical Research Programs
How Do I Apply - Application Process
| | |||||||||||
 | | Nomination Package Checklist
| |||||||||
Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopath
There are some very interesting pieces of information in this abstract (including ovarian/clear cell/endometrioid cell types:
Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Tuesday, December 15, 2009
In conversation with Dr. Brent Zanke | BioTuesday
The founder and chairman of ArcticDx
What’s the status of your colon cancer test?
Colo-Risk is undergoing clinical testing Colo-Risk is undergoing clinical testing in collaboration with McMaster University in Hamilton. The core intellectual property is owned jointly by Cancer Care Ontario, which runs provincial screening programs, and McGill University. There are additional pieces of IP that we are in the process of acquiring. And we’re hoping it will be launched next year as the first product of its kind to predict an individual’s risk of developing colorectal cancer.
The test combines your genetic predisposition to colorectal cancer with environmental risk factors like age, history of smoking and body mass index to come up with your life-time risk of developing the disease. So, if you’re carrying genes that say you’ve got a 30% or 40% likelihood of getting colon cancer at some time in my life, you will be vigilant in early screening programs. If you could tell from your genetic makeup that you have a 1% chance, that would be in keeping with your risk of developing a lot of other things as well.
Physician Referral for Fertility Preservation in Oncology Patients: A National Study of Practice Behaviors
less than 50% follow guidelines
Monday, December 14, 2009
Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer)
Note: This full free access paper is dated 2007 but has 2009 references including Li-Fraumeni Syndrome.
Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer)
PharmaLive: Pfizer Extends Commitment to Help Unemployed Americans
PharmaLive: Pfizer Extends Commitment to Help Unemployed Americans: "Medicines Assistance for Those who Are in Need) patient assistance program for an additional year, through December 31, 2010"
ScienceDirect - Social Science & Medicine : Interpersonal perception in the context of doctor–patient relationships: A dyadic analysis of doctor–patient communication
Gene Variant That Increases Ovarian Cancer Risk Discovered
Gene Variant That Increases Ovarian Cancer Risk Discovered: "After eight years of searching, Gayther and colleagues found an SNP on chromosome 9 that was uniquely linked to ovarian cancer. Each of us has 23 pairs of chromosomes, each 'copy' in the pair comes from one biological parent.
In collaboration with the international Ovarian Cancer Association Consortium (OCAC) they confirmed the finding in another group of 7,000 women with ovarian cancer and 10,000 women without the disease. The samples came from women all over the world."
Sunday, December 13, 2009
SOCS1/p53: Scientists discover molecule that acts as natural cancer defense, Cancer Treatment
Scientists discover molecule that acts as natural cancer defense, Cancer Treatment
Scientists from Canada have found a natural defense mechanism for cancer prevention. Cytokines have long been known to produce diseases that include cancer, diabetes, and chronic inflammation. The new study identifies a link between the SOCS1 molecule and the p53 gene that is found to be lost among a majority of cancer patients.
The new research surprisingly showed the link between SOCS1 molecule and cancer. According to a lead author and Université de Montréal student, Viviane Calabrese The research team didn't anticipate that SOCS1 would turn out to be linked to p53, the master regulator of natural anticancer defenses. We were surprised to realize that SOCS1 was directly linked to p53."
Saturday, December 12, 2009
Woman wins damages after errors by Winchester hospital (From Hampshire Chronicle)
one of the very few lawsuits ever won in ovarian cancer (irrespective of country)
Friday, December 11, 2009
Thursday, December 10, 2009
MicroRNAs in Ovarian Carcinomas
| Medline Abstract
N Dahiya, Lab Cell Molec Biol, NIH, Baltimore, United States.
|  | |||||||||||
| ||||||||||||
| ||||||||||||
| ||||||||||||
| The molecular mechanisms involved in epithelial ovarian cancer initiation and progression are just beginning to be elucidated. In particular, it has become evident that microRNAs (miRNAs), a class of molecules that post-trancriptionally regulates gene expression, play a major role in ovarian tumorigenesis. Several miRNA profiling studies have identified changes in miRNA patterns that take place during ovarian cancer development. While most deregulated miRNAs are down-regulated in cancer, and may therefore act as tumor suppressors, others are elevated and may represent novel oncogenes in this disease. A number of miRNAs identified as aberrantly expressed in ovarian carcinoma have been shown to have important functional roles in cancer development and may therefore represent targets for therapy. In addition, some of the miRNA patterns may have prognostic significance. The identification of functional targets represents a major hurdle in our understanding of miRNA function in ovarian carcinoma, but significant progress is being made. It is hoped that a better understanding of the miRNA expression and roles in ovarian cancer may provide new avenues for the detection, diagnosis, and therapy of this deadly disease. PMID: 19903743 | ||||||||||||
Wednesday, December 09, 2009
Mantra 2009 programme conference outline including abstracts
Cancer Family Study, Australasian Colorectal
Cancer Family Study, Australian Ovarian Cancer
Study, Family Cancer Clinics of Australia and New
Zealand & kConFab
Lynch syndrome: still not a familiar picture.
CASE PRESENTATION: A large Lynch syndrome family with 15 affected family members and involvement in 7 organs is reported. It illustrates a lack of awareness and knowledge about this hereditary tumor syndrome among doctors as well as patients. None of the described family members underwent presymptomatic screening on the basis of the family history.
red flags for familal forms of cancer susceptibility - excerpt
The general clinical features that raise the suspicion of a familial form of cancer susceptibility in a patient diagnosed with any type of malignancy include [1]:
* A cancer that occurs at an unusually young age compared with its usual presentation
* The development of multiple tumors in a single organ, or bilateral development in tumors in paired organs
* The development of more than one primary tumor of any type
* A family history of cancer of the same type or related type in one or more first-degree relatives
* A high rate of cancer occurrence in the family
* Cancer occurring in an individual or within a family with congenital anomalies or birth defects
Expanded Extracolonic Tumor Spectrum in MUTYH-Associated Polyposis
Results
Duodenal polyposis occurred in 17% of cases; the relative risk (SIR) of duodenal cancer was 129 (95% confidence interval [CI]: 16–466), whereas the lifetime risk was 4%. The incidence of extraintestinal malignancies among cases was almost twice that of the general population (SIR: 1.9; 95% CI: 1.4–2.5), with a lifetime risk of 38%. We observed a significant increase in the incidence of ovarian, bladder, and skin cancers (SIR: 5.7, 7.2, and 2.8, respectively) and a trend of increased risk of breast cancer among cases. The median ages of onset of these 4 malignancies ranged from 51 to 61 years. In contrast to familial adenomatous polyposis, no desmoid tumors were observed, but sebaceous gland tumors, characteristic of the Muir-Torre variant of Lynch syndrome, occurred in 5 patients.
Conclusions
The relative risks for several extraintestinal malignancies increased in patients with MAP, but based on the spectrum of cancers (which overlaps with that of Lynch syndrome) and the relatively advanced age at onset, intensive surveillance measures other than frequent endoscopy are unlikely to be helpful to patients with MAP.
Three synchronous primary carcinomas in a patient with HNPCC associated with a novel germline mutation in MLH1: Case report
note fig. 2 and reference to ovarian cancer (?)
Three synchronous primary carcinomas in a patient with HNPCC associated with a novel germline mutation in MLH1: Case report
Three synchronous primary carcinomas in a patient with HNPCC associated with a novel germline mutation in MLH1: Case report
Tuesday, December 08, 2009
gene called MAGP2 -- not previously associated with any type of cancer -- was overexpressed in papillary serous ovarian tumors of patients
A multi-institutional study has identified a potential personalized treatment target for the most common form of ovarian cancer. In the December 8 issue of Cancer Cell, the research team describes finding that a gene called MAGP2 -- not previously associated with any type of cancer -- was overexpressed in papillary serous ovarian tumors of patients who died more quickly. They also found evidence suggesting possible mechanisms by which MAGP2 may promote tumor growth.
VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE | Unique genetic pathology centre set to change the way we treat cancer
"...ovarian cancer is at least five distinct diseases..."
Patient Relations "Road Show" at University Health Network :: Vol. 12 No. 4 2009 :: Healthcare Quarterly :: Longwoods Publishing
Patient Relations "Road Show" at University Health Network :: Vol. 12 No. 4 2009 :: Healthcare Quarterly :: Longwoods Publishing: "Overall, across all sites, the results of our program have generally been positive; 53.9% felt that the in-service met their expectations, and 45.9% felt that their expectations were exceeded."
A Patient's Right to be Believed :: Essays :: Longwoods Publishing
A Patient's Right to be Believed :: Essays :: Longwoods Publishing: "When I speak at public events about the power of online patient stories for healthcare decision-making, some in the healthcare industry (clinicians and non-clinicians) dismiss these millions of narratives as meaningless chatter with no validity. Interestingly, they're more often accepted as truth when they praise healthcare providers; they're harder to accept when they're critical."
Morphologic Changes in Ovarian Carcinoma After Neoadjuvant Chemotherapy: Report of a Case Showing Extensive Clear Cell Changes Mimicking Clear Cell Ca
Morphologic Changes in Ovarian Carcinoma After Neoadjuvant Chemotherapy: Report of a Case Showing Extensive Clear Cell Changes Mimicking Clear Cell Carcinoma
Clinical Value of Morphometric and DNA Flow Cytometric Variables as Independent Predictors of Survival in Epithelial Ovarian Carcinoma: A 5-year Follo
Clinical Value of Morphometric and DNA Flow Cytometric Variables as Independent Predictors of Survival in Epithelial Ovarian Carcinoma: A 5-year Follow-up Study
Monday, December 07, 2009
Increased incidence of postoperative infections during prophylaxis with cephalothin compared to doxycycline in intestinal surgery
Results
The SSI in the colorectal department increased from 19% to 30% (p = 0.002) when doxycycline was substituted with cephalothin and decreased to 17% when we changed back to doxycycline (p = 0.005). In the gynaecology department the surgical site infection rate did not increase significantly. Subgroup analysis showed major changes in infections in rectal resections from 20% to 35% (p = 0.02) and back to 12% (p = 0.003).
new expression - "in the fullness of time" 10,000 patients' data a click away - thestar.com
10,000 patients' data a click away - thestar.com
"As for the old paper files, eHealth's interim chair says: "In the fullness of time, we will be rid of them.""
Sunday, December 06, 2009
Expert questions continuing H1N1 vaccinations
(reference/search prior blog posting 'H1N1 and cancer' letter:
"...But the benefit diminishes the farther into the future we go, and he said other public health programs have suffered as staff and resources were redeployed to the H1N1 campaign."
Safety of Bevacizumab in Advanced Ovarian and Müllerian Cancers: A Review: Abstract and Introduction
Safety of Bevacizumab in Advanced Ovarian and Müllerian Cancers: A Review: Abstract and Introduction
The Impact of Complete Surgical Staging Upon Survival in Early-Stage Ovarian Clear Cell Carcinoma: A Multi-institutional Retrospective Study
Although the study was a limited retrospective study, the impact of peritoneal cytology status was more important than complete surgical staging procedure in CCC patients. More effective treatment modality was warranted, especially for CCC cases positive for malignant peritoneal cytology.
Preoperative CA-125 Levels in 123 Patients With Borderline Ovarian Tumors: A Retrospective Analysis and Review of the Literature
From a clinical perspective, we believe, on base of the results of this study and the literature, that preoperative discrimination using CA-125 level is especially difficult between patients with stage I ovarian cancer and the group of patients with serous and/or advanced-stage BOTs.
Saturday, December 05, 2009
This test can spare women from chemo. But they can't get it here - The Globe and Mail
This test can spare women from chemo. But they can't get it here - The Globe and Mail
My response: some of the public's opinions which, as usual, were way off target to the original focus of the article: It's always a great transformation of opinion when those without a cancer diagnosis are diagnosed. It's very nice to know there are so many who believe in each paying for their own healthcare except...that's nice. But, envision your neighbour, your family member, your friend who cannot. Envision if it is your neighbour's child. Nice that we seem to have come to such a one-person self-centerness that we cannot see beyond the small picture of one.
Response: Does Morphine Stimulate Cancer Growth? | GeriPal - A Geriatrics and Palliative Care Blog
Does Morphine Stimulate Cancer Growth? | GeriPal - A Geriatrics and Palliative Care Blog
Response to the dialogues:
-
While the media and pharma are often criticized in situations such as this, there is the communication factor - good or bad. The value to patients of harm vs benefit is that the information is available and sufficient enough for patients to question, research and also take the information for discussion to their professional caregivers. The e-patient communities welcome dialogues but not in an exclusive setting which is absent their participation.
- December 5, 2009 8:57 AM
Friday, December 04, 2009
Radiation recall dermatitis triggered by multi-tar... [Anticancer Drugs. 2009] - PubMed result
Radiation recall dermatitis triggered by multi-tar... [Anticancer Drugs. 2009] - PubMed result: "Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib"
Tumor type and substage predict survival in stage I and II ovarian carcinoma: Insights and implications
Note: there is supplemental data that can be downloaded (word document) which is attached to this abstract - see link to view
Conclusions
A subset of ovarian carcinoma patients with an excellent outcome can be identified based on tumor type (endometrioid or mucinous) and stage (Ia or Ib). Type is more reproducibly assigned than grade and identifies a larger cohort of women with stage I/II ovarian carcinoma with favorable outcomes (12.2% vs. 6.5%), and therefore is superior to grade in estimating risk of death from ovarian carcinoma.
Gynecologic Oncology : Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: Results of a multicenter phase II study of the northeastern German society of gynecological oncology
Gynecologic Oncology : Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: Results of a multicenter phase II study of the northeastern German society of gynecological oncology
AHRQ Patient Safety Network - Patient Safety Primers
AHRQ Patient Safety Network - Patient Safety Primers: "The culture of individual blame still dominant and traditional in health care undoubtedly impairs the advancement of a safety culture. One issue is that, while 'no blame' is the appropriate stance for many errors, certain errors do seem blameworthy and demand accountability. In an effort to reconcile the twin needs for no-blame and appropriate accountability, the concept of 'just culture' is being introduced."
Thursday, December 03, 2009
Senate Affirms Screening Mammography for 40-Year-Olds - in Washington
In a 61 to 39 vote, the Senate dealt a significant blow to the power and credibility of the U.S. Preventive Services Task Force (USPSTF), by essentially deciding to disregard the task force's recent recommendation that women under 50 shouldn't undergo routine mammograms....
Drug company contributes $9 million to B.C.'s fight against cancer
Research in ovarian cancer will focus on identifying new biomarkers for diagnostic purposes as well as therapeutic targets
Recreational physical activity and risk of epithelial ovarian cancer
CONCLUSIONS: Our findings are compatible with an overall reduction in risk of invasive epithelial ovarian cancer associated with recreational activity but suggest that this association may differ in women with different histologic types of disease. Inconsistent findings across studies that have considered histologic type indicate that this issue is not yet resolved.
Wednesday, December 02, 2009
James Kreppner’s Obituary by the Toronto Star.
James Kreppner Death Notice
"KREPPNER, James Rudolf - March 6, 1962 to May 14, 2009 The world has lost an extraordinary human being. It is with profound sadness that the family announces the passing of James, a man possessed of a brilliant mind, gentle soul and tender heart, after a long, courageous and feisty battle with illness, on May 14, 2009, in his 47th year due to HIV and Hepatitis C-related complications...James was a highly respected, articulate and exemplary activist who represented the true meaning of fairness and kindness."
response to prior letter: HINI and Cancer
Note/background: Please reference prior blog postings Nov 1-5th, 2009 regarding the apparent lack of access to care of an ovarian cancer woman and the systemic issues surrounding the H1N1.
email response (better late than never) December 2, 2009 4:57 pm:
"Thank you for writing and bringing to my attention your concerns regarding the government’s handling of the H1N1 vaccine roll out. As you are aware, the vaccine is now available to all members of the public.
Your views and comments are appreciated and helpful to my work as Leader of Canada’s New Democrats.
Between the conflicting messages, queue jumping, and sole sourced contracts; we feel the federal government could have done a better job handling the distribution of the vaccine. NDP Health Critic Judy Wasylycia-Leis continues to be our lead on this issue and you can review her work by visiting: http://www.judywl.ndp.ca/news/health.
Looking forward, we will continue to press the federal government to take a proper role in helping Canadians stay healthy and providing access to treatment when needed through:
- promoting healthy living
- hiring and training more doctors and nurses
- creating a pan-Canadian home care program
- ensuring prescription medicines are affordable
If you are interested in our plans to improve health care in Canada, I encourage you to check for details here: http://www.ndp.ca/platform/healthcare.
Again, thank you for sharing your views and comments as they helpful to my work as Leader of Canada’s New Democrats. All the best.
Sincerely,
Jack Layton, MP (Toronto-Danforth)
Leader, Canada's New Democrats"
14-3-3σ, the double-edged sword of human cancers
highly technical paper, but the issues that always seem to find ovarian cancer at 'odds' with other cancers:
Despite the above findings that 14-3-3σ expression correlates with and may predict poor prognosis of breast, colorectal, prostate, and pancreatic cancers, opposite observations have also been made in other cancers including endometrium [61] and ovary [30], where it was found that the absence or low expression level of 14-3-3σ predicted poor survival or showed no correlation (see Table 1). In another study of 192 cases of ovarian cancer patients, no significant correlation between 14-3-3σ expression and survival was found [62]. Thus, it is possible that 14-3-3σ in prognosis prediction is cancer type dependent, and more detailed studies on this issue will be needed.
In response to recent media: Does Morphine Stimulate Cancer Growth? | GeriPal - A Geriatrics and Palliative Care Blog
Please read the full article/discussion. Many questions were asked and responses given which may be helpful for many.
Over the last week Reuters, ABC news, MSNBC, BBC News, and more than 75 other outlets reported on how two "two new studies add to growing evidence that morphine and other opiate-based painkillers may promote the growth and spread of cancer cells." What was most shocking were the headlines used to promote the stories:
* Morphine 'might spread cancer' (BBC News)
* Morphine May Help Tumors Spread in Cancer Patients (US News and World Reports)
* Pain drug morphine may accelerate cancer growth (Reuters, ABC News)
* Common Pain Relief Medication May Encourage Cancer Growth (Science Daily)
Tuesday, December 01, 2009
Cochrane Collaboration meta-analysis: Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data
The authors of this new meta-analysis concluded that ESA treatment shortens survival. They could not identify with certainty any subgroup of patients at either increased or decreased risk of dying when taking ESAs. With their doctors' help, cancer patients should consider the risks of taking ESA against the risks of a blood transfusion. Be aware, however, that uncertainties remain about the magnitude of each.
favourite quote of the day
"... if you are really effective at what you do, 95% of the things said about you will be negative." Scott Boras
(incompetent) Ontario Health Ministry press release: Improving Patient Care in Ontario
email to Minister:
Please immediately hire a new writer. This has to be the worst press release I have ever read and has a new found meaning in 'dumbing it down'. Give the public a bit, just a bit of credit for health literacy. Also include in the future a direct link to the bill. Was this reviewed by a panel of patients/citizens before it was released? No need to answer as it is obvious.
Ontario
Improving Patient Care in Ontario
December 1, 2009 2:13 PM
Ontario has passed Third Reading of Bill 179 that would improve access to health care for Ontarians by allowing care providers to use all of their training to perform their jobs and to work more effectively in teams. The proposed legislation would:
Expand What Health Care Providers Do
Health profession Acts (e.g., Nursing Act) under the Regulated Health Professions Act would be changed to allow providers to perform specific health care actions (controlled acts) or order diagnostic tests:
Health Care Provider
Proposed New Controlled Acts and Powers
Nurse Practitioners
* Apply specified forms of energy (e.g., diagnostic ultrasound);
* Set or cast a fracture or dislocation of a joint
Pharmacists
* Prick or lance skin to educate a patient
Physiotherapists
* Tell patients their diagnosis
* Treat a wound
* Insert an instrument, hand or finger into certain body openings for assessment or rehabilitation of the pelvic musculature
* Order certain forms of energy (e.g., diagnostic ultrasound)
Midwives
* Tell patients their diagnosis
* Give suppository drugs
* Place a tube in the nose or mouth of a newborn
* Take blood samples from fathers and donors
Dietitians
* Prick skin to check a patient's blood readings
Medical Radiation Technologists
* On the order of a physician be able to:
- perform procedures below the skin (e.g., give a needle)
- suction a tracheotomy
- put contrast media into certain body openings and artificial openings into the body
- put an instrument, hand or finger past certain body openings and artificial openings into the body.
Professional Practice Changes Regarding Drugs
Health professions Acts (e.g., Pharmacy Act) under the Regulated Health Professions Act would be changed to give providers the power to administer, prescribe, dispense, compound (mix), sell and use drugs as follows:
Health Care Provider
Drug Authorities Proposed to be Added
Chiropodists and Podiatrists
Give a patient certain substances by inhalation
Dental hygienists
Prescribe, dispense, sell or mix certain drugs
Dentists
Sell or mix drugs (can already prescribe and dispense)
Midwives
Give a patient any substance on the order of a physician
Naturopaths
Prescribe, dispense, mix and sell certain drugs.
Nurse practitioners
Prescribe, dispense, mix and sell drugs without restrictions.
Pharmacists
Prescribe certain drugs to manage patient health
Give certain substances through injection and inhalation to demonstrate their use or to educate patients
Physiotherapists
Give certain substances by inhalation as ordered by authorized persons (e.g., a physician)
Respiratory therapists
Independently give a patient certain substances by inhalation
Increase Ability to Order X-Rays
Regulations would be changed under the Healing Arts Radiation Protection Act to allow:
* Nurse practitioners to order any X-rays
* Physiotherapists to order X-rays subject to conditions
CONTACTS
* David Jensen
Communications Branch
416-314-6197
media@nullmoh.gov.on.ca
* Ivan Langrish
Minister's Office
416-326-3986
* For public inquiries call ServiceOntario, INFOline
1-866-532-3161
null(Toll-free in Ontario only)
* Media Line
Toll-free: 1-888-414-4774
GTA: 416-314-6197
media@nullmoh.gov.on.ca
Ministry of Health and Long-Term Care
ontario.ca/health
© Queen's Printer for Ontario, 2008 - 2009 - Last Modified:December 01, 2009
Q & A transcript: Outlook: Fighting a smarter war on cancer - washingtonpost.com
"Outlook: Fighting a smarter war on cancer"
Cancers, infections, and endocrine diseases in women with endometriosis
"While ovarian cancer and melanoma were significantly more common than in the general population, breast cancer was surprisingly less common."
Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence....
Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients.
Monday, November 30, 2009
CureToday.com: Blogs - Kathy LaTour - Do you understand your diagnosis?
"'I literally wrote the book but it made no difference,'"
Just medicare: what's in, what's out ... - Google Books
This book is available free through Google books or can be purchased online.
Malignant Ascites Symptom Cluster in Patients Referred for Paracentesis
click on the pdf icon for full free access the paper
New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates
New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents
Sunday, November 29, 2009
OCATS requires your help
Message forwarded: website http://www.ocats.ca
H E L P!!! We know it’s Grey Cup weekend, and Christmas is coming, and we’ve all got better things to do. But, imagine in the middle of all this our Ministry of Health, without any consultations or even contacting the doctors with urgent and critical issues CANCELLED the meeting where they promised they would finally have a solution for us.
H E L P!!! We know it’s Grey Cup weekend, and Christmas is coming, and we’ve all got better things to do. But, imagine in the middle of all this our Ministry of Health, without any consultations or even contacting the doctors with urgent and critical issues CANCELLED the meeting where they promised they would finally have a solution for us.
You know that for over a year now, since spring 2008, we’ve been asking for proper support for our gynecologic oncologists serving southern Saskatchewan. In every other jurisdiction these specialists working in a clinical setting (i.e. a hospital!) with proper medical, nursing, pathology, radiology support. But OH NO, not in Regina! Here we expect these doctors to continue struggling to find simple office space to examine their patients and keep files. They have to go out and find their own nursing, after hours and medical support. This is beyond BIZARRE! In the medical issues business, this has got to be something we can actually figure out and fix? No?
Last meeting, I presented a solution for the interim. Reimburse the doctors immediately for their private practice space, get a proper nurse in their for them. This is minimal, while a real solution is sought. Gov’t response – NONE, NADA.
This meeting was put off because not only is there no solution yet, no one has even contacted the doctors, visited them, observed their needs, nothing. NADA. Do we want/need these specialists - highly sought out and highly skilled experts who need to be in the operating room or examining patients – to be out looking for appropriate office space, trying to figure out how to PAY for it, recruiting for their own support staff, filling the supply cabinets????
Remember in the spring when a Regina gyne onc told the media that the working conditions had become unworkable? This meant the specialists were considering closing their private practices. This meant patients had to be shipped out of Regina? Well – they were told a lot of promises, as was OCATS. They were told a solution would come before Sept 1st, then they said oh that was summer; we’ll get it done by fall. Well fall has been deferred til next year! Enough is Enough!!!! Evidently the only time the Ministry seriously listens is when women in large numbers speak loudly. The legislative assembly will be sitting for only a few more days.
P l e a s e h e l p u s s p e a k l o u d l y !
Write to: The Honourable Don McMorris, Minister of Health, Government of Saskatchewan, Minister's Office, Room 302, Legislative Building, 2405 Legislative Drive, Regina, SK, S4S 0B3, Fax (306) 787-0237, minister.he@gov.sk.ca, sophie.ferre@gov.sk.ca
Copy to: (this is really the job of the Regina Qu’Appelle Health District) Dr. Dwight Nelson, CEO RQHD dwight.nelson@rqhealth.ca, Dr. Chris Vuksic, Chris.Vuksic@rqhealth.ca
And Copy to: Dwain Lingenfelter, Leader of the Official Opposition and Opposition Health Critic, Judy Junor, c/o Dwight Yasinowsky at dyasinowski@ndpcaucus.sk.ca
Short, Sweet and To the Point is all you need:
Dear Minister – Ovarian cancer patients don’t have enough time for this continue bureaucratic fumbling. There are highly paid administrators and executives are various levels who should be able to resolve the issue of poor working conditions for Gynecologic Oncologists serving Southern Saskatchewan. Enough is enough. At minimum get these specialist’s office space and support staff in place and paid for before the end of the year.
John L. Marshall -- How health-care reform can cure cancer - washingtonpost.com
"At the moment, there is a giant disconnect between patients, the cost of care and the clinical benefit of the treatment -- a disconnect that has caused us to lose perspective. When it comes to cancer care, we're not getting what we pay for.
Cancer medicine is often regarded as an area of significant progress and clinical research, so we should be able to tell without much difficulty what kinds of treatment are valuable and what kinds aren't.
But given that 80 percent of my patients will die of their cancer, it's clear that we have not found an "optimum" therapy."
CBC News - Health - Ontario expands access to costly cancer drug
CBC News - Health - Ontario expands access to costly cancer drug
Ontario is expanding access to a cancer drug that was the subject of a scathing report by the province's ombudsman earlier this year.....
news item: see - Top 10 most common primary site cancers diagnosed with more than 1 cancer
my view: according to ACS stats, but I full expect that these numbers are very low estimates
Subscribe to:
Posts
(
Atom
)
